JP2011126917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011126917A5 JP2011126917A5 JP2011065075A JP2011065075A JP2011126917A5 JP 2011126917 A5 JP2011126917 A5 JP 2011126917A5 JP 2011065075 A JP2011065075 A JP 2011065075A JP 2011065075 A JP2011065075 A JP 2011065075A JP 2011126917 A5 JP2011126917 A5 JP 2011126917A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition
- red blood
- administered
- serum complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 10
- 210000003743 erythrocyte Anatomy 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 230000024203 complement activation Effects 0.000 claims 5
- 238000004820 blood count Methods 0.000 claims 3
- 229960002224 eculizumab Drugs 0.000 claims 3
- 210000001995 reticulocyte Anatomy 0.000 claims 3
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 230000011132 hemopoiesis Effects 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229960003284 iron Drugs 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/771,552 | 2004-02-03 | ||
| US10/771,552 US20050169921A1 (en) | 2004-02-03 | 2004-02-03 | Method of treating hemolytic disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551599A Division JP2007520494A (ja) | 2004-02-03 | 2005-02-03 | 溶血性疾患の処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013145341A Division JP5873047B2 (ja) | 2004-02-03 | 2013-07-11 | 溶血性疾患の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011126917A JP2011126917A (ja) | 2011-06-30 |
| JP2011126917A5 true JP2011126917A5 (enExample) | 2012-01-19 |
Family
ID=34808492
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551599A Withdrawn JP2007520494A (ja) | 2004-02-03 | 2005-02-03 | 溶血性疾患の処置方法 |
| JP2011065075A Withdrawn JP2011126917A (ja) | 2004-02-03 | 2011-03-23 | 溶血性疾患の処置方法 |
| JP2013145341A Expired - Lifetime JP5873047B2 (ja) | 2004-02-03 | 2013-07-11 | 溶血性疾患の処置方法 |
| JP2015015028A Withdrawn JP2015083611A (ja) | 2004-02-03 | 2015-01-29 | 溶血性疾患の処置方法 |
| JP2017000897A Pending JP2017057234A (ja) | 2004-02-03 | 2017-01-06 | 溶血性疾患の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551599A Withdrawn JP2007520494A (ja) | 2004-02-03 | 2005-02-03 | 溶血性疾患の処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013145341A Expired - Lifetime JP5873047B2 (ja) | 2004-02-03 | 2013-07-11 | 溶血性疾患の処置方法 |
| JP2015015028A Withdrawn JP2015083611A (ja) | 2004-02-03 | 2015-01-29 | 溶血性疾患の処置方法 |
| JP2017000897A Pending JP2017057234A (ja) | 2004-02-03 | 2017-01-06 | 溶血性疾患の処置方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20050169921A1 (enExample) |
| EP (7) | EP2520311A3 (enExample) |
| JP (5) | JP2007520494A (enExample) |
| KR (1) | KR101197799B1 (enExample) |
| CN (4) | CN103446584A (enExample) |
| AU (1) | AU2005209854B2 (enExample) |
| CA (1) | CA2554632A1 (enExample) |
| CY (1) | CY1113190T1 (enExample) |
| DK (1) | DK1720571T3 (enExample) |
| ES (1) | ES2389093T3 (enExample) |
| IL (2) | IL177003A0 (enExample) |
| NZ (1) | NZ549328A (enExample) |
| PL (1) | PL1720571T3 (enExample) |
| PT (1) | PT1720571E (enExample) |
| SI (1) | SI1720571T1 (enExample) |
| WO (1) | WO2005074607A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20070116710A1 (en) * | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| EP3056218A1 (en) * | 2004-05-14 | 2016-08-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006107708A1 (en) * | 2005-04-04 | 2006-10-12 | Alexion Pharmaceuticals, Inc. | Treatment of disease caused by excess free hemoglobin |
| ES2551202T5 (es) * | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| EP1988882B1 (en) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| DK2359834T5 (en) * | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| EP3028716B1 (en) | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
| CN106084054A (zh) * | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| RS64039B1 (sr) * | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| CN106390117A (zh) * | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
| US20110124019A1 (en) * | 2009-11-25 | 2011-05-26 | The Charlotte-Mecklenburg Hospital Authority | Method of using carbonic anhydrase to detect hemolysis |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| CN105218674A (zh) * | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| AU2015230852B2 (en) * | 2011-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | High concentration antibody formulations |
| KR20220044616A (ko) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| CN104205155A (zh) * | 2012-03-16 | 2014-12-10 | 亚力克恩制药公司 | 给接受补体抑制剂的患者分配补体抑制药物的方法 |
| CA3087933A1 (en) * | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| WO2014160958A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| WO2015058143A1 (en) | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| JP2018511557A (ja) | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | ２種以上の抗ｃ５抗体の組み合わせおよび使用方法 |
| US20190135903A1 (en) * | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| IT201600121482A1 (it) * | 2016-11-30 | 2018-05-30 | Univ Degli Studi Di Verona | Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme |
| CN110167961A (zh) | 2017-01-31 | 2019-08-23 | 中外制药株式会社 | 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法 |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| MY210523A (en) | 2018-08-01 | 2025-09-29 | Univ Osaka | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| CN114929273A (zh) | 2019-07-31 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| AU2020319677A1 (en) | 2019-07-31 | 2022-01-06 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5650825A (en) * | 1995-03-31 | 1997-07-22 | Matsushita Electric Corporation Of America | Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream |
| DE19826743A1 (de) * | 1998-06-16 | 1999-12-23 | Bayer Ag | Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere |
| ATE320450T1 (de) * | 2000-12-05 | 2006-04-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
| WO2003081206A2 (en) * | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
-
2004
- 2004-02-03 US US10/771,552 patent/US20050169921A1/en not_active Abandoned
-
2005
- 2005-02-03 US US11/050,543 patent/US20050191298A1/en not_active Abandoned
- 2005-02-03 EP EP12169508A patent/EP2520311A3/en not_active Withdrawn
- 2005-02-03 CN CN2013103817575A patent/CN103446584A/zh active Pending
- 2005-02-03 AU AU2005209854A patent/AU2005209854B2/en not_active Expired
- 2005-02-03 EP EP12169526A patent/EP2522364A1/en not_active Withdrawn
- 2005-02-03 EP EP12169513A patent/EP2522362A1/en not_active Withdrawn
- 2005-02-03 CN CNA2005800106310A patent/CN1938047A/zh active Pending
- 2005-02-03 EP EP15150658.1A patent/EP2910253A1/en not_active Withdrawn
- 2005-02-03 ES ES05712607T patent/ES2389093T3/es not_active Expired - Lifetime
- 2005-02-03 CN CN201410147793.XA patent/CN103977402A/zh active Pending
- 2005-02-03 EP EP05712607A patent/EP1720571B9/en not_active Revoked
- 2005-02-03 CN CN201410147935.2A patent/CN103977403A/zh active Pending
- 2005-02-03 NZ NZ549328A patent/NZ549328A/en not_active IP Right Cessation
- 2005-02-03 CA CA002554632A patent/CA2554632A1/en not_active Abandoned
- 2005-02-03 KR KR1020067017880A patent/KR101197799B1/ko not_active Ceased
- 2005-02-03 EP EP12169519A patent/EP2522363A1/en not_active Withdrawn
- 2005-02-03 PL PL05712607T patent/PL1720571T3/pl unknown
- 2005-02-03 SI SI200531579T patent/SI1720571T1/sl unknown
- 2005-02-03 WO PCT/US2005/003225 patent/WO2005074607A2/en not_active Ceased
- 2005-02-03 JP JP2006551599A patent/JP2007520494A/ja not_active Withdrawn
- 2005-02-03 EP EP12169343A patent/EP2522361A1/en not_active Withdrawn
- 2005-02-03 DK DK05712607.0T patent/DK1720571T3/da active
- 2005-02-03 PT PT05712607T patent/PT1720571E/pt unknown
-
2006
- 2006-07-20 IL IL177003A patent/IL177003A0/en unknown
-
2009
- 2009-11-19 US US12/621,792 patent/US20100068202A1/en not_active Abandoned
-
2010
- 2010-10-12 US US12/902,617 patent/US20110086040A1/en not_active Abandoned
-
2011
- 2011-03-23 JP JP2011065075A patent/JP2011126917A/ja not_active Withdrawn
- 2011-12-22 US US13/335,518 patent/US20120308559A1/en not_active Abandoned
-
2012
- 2012-08-30 CY CY20121100783T patent/CY1113190T1/el unknown
-
2013
- 2013-07-11 JP JP2013145341A patent/JP5873047B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-29 JP JP2015015028A patent/JP2015083611A/ja not_active Withdrawn
- 2015-08-06 IL IL240410A patent/IL240410A0/en unknown
-
2017
- 2017-01-06 JP JP2017000897A patent/JP2017057234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011126917A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| JP2015131795A5 (enExample) | ||
| JP2015535209A5 (enExample) | ||
| JP2012050465A5 (enExample) | ||
| JP2017534618A5 (enExample) | ||
| JP2019505585A5 (enExample) | ||
| RU2013155618A (ru) | Индукция иммунологической толерантности, используя метотрексат | |
| JP2018509388A5 (enExample) | ||
| JP2019528285A5 (enExample) | ||
| Han et al. | BK virus-associated hemorrhagic cystitis after pediatric stem cell transplantation | |
| JP2014513065A5 (enExample) | ||
| JP2009508822A5 (enExample) | ||
| JP2017519762A5 (enExample) | ||
| JP2017520562A5 (enExample) | ||
| Imamura et al. | Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure design and rationale of the AQUA-TLV study | |
| Fedorak et al. | VSL3 probiotic mixture induces remission in patients with active ulcerative colitis | |
| Kasuya et al. | Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus | |
| JP2017527613A5 (enExample) | ||
| JP2011527317A5 (enExample) | ||
| RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Basu et al. | 87 SINGLE USE OF ROMIPLOSTIM THROMBOPOIETIN ANALOGUE IN SEVERE THROMBOCYTOPENIA FOR OUTPATIENT PERCUTANEOUS LIVER BIOPSY IN PATIENTS WITH CHRONIC LIVER DISEASE-A RANDOMIZED DOUBLE BLINDED PROSPECTIVE TRIAL | |
| JP2015536999A5 (enExample) | ||
| Chan et al. | Making Use of Avacopan in Clinical Practice |